H.C. Wainwright lowered the firm’s price target on Valneva (VALN) to $17 from $18 and keeps a Buy rating on the shares following the Q4 report. The firm cites reduced sales estimates for Ixchiq for the target drop.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Valneva Reports 2024 Financial Performance and Optimistic 2025 Outlook
- Valneva jumps 19% after chikungunya vaccine wins UK approval
- MHRA grants Valneva marketing authorization for chikungunya vaccine
- Valneva’s Vaccine Market Expansion and Revenue Growth Drives Buy Rating with $18 Price Target
- Valneva’s Chikungunya Vaccine Gains UK Approval, Expanding Global Reach